Michael J. Morris, MD

About Me

I am a board-certified medical oncologist who specializes in treating men with prostate cancer, particularly those who have metastatic disease (disease that has spread to distant organs) or who are at high risk of developing metastatic disease.

Much of my research bridges the fields of medical oncology and nuclear medicine. I am working with colleagues on Memorial Sloan Kettering’s Nuclear Medicine Service to develop radiopharmaceuticals — liquid drugs that deliver radiation therapy directly to cancer cells or to the areas in the skeleton that harbor prostate cancer cells. I am exploring one class of these drugs, called bone-seeking radiopharmaceuticals, in combination with chemotherapy. I am also exploring a new form of bone-seeking radiopharmaceutical that has fewer side effects in the bone marrow.

Another research interest is developing new ways to image prostate cancer in the bones using unique, prostate-cancer-specific PET scans and other new imaging modalities. This type of imaging not only provides an insight into where the prostate cancer is located, but informs us about its biology as well.

Finally, I am interested in finding ways to prevent metastatic disease in patients who have undergone prostatectomy but whose PSA is rising rapidly. I am leading an international study for these patients in which we hope to determine whether early and aggressive treatment can delay, if not prevent, the development of metastases.

One of my priorities is increasing patient access to clinical trials. I am currently involved in the development of the Prostate Cancer Clinical Trials Consortium (PCCTC), an initiative designed to increase patient access to clinical trials across the country. I also sit on Cancer and Leukemia Group B (CALGB)’s genitourinary committee, a National Cancer Institute-designated group composed of local and academic oncology centers, to facilitate clinical testing of new drugs throughout the country. In addition, I am very involved with the American Society of Clinical Oncology (ASCO); I am on ASCO’s Education Committee and chair of the Genitourinary Scientific Track.

  • Clinical Expertise: Prostate Cancer; New Investigational Agents
  • Awards and Honors: Castle Connolly: New York Magazine Top Doctors (2013; 2015-2018)
  • Languages Spoken: English
  • Education: MD, Mount Sinai School of Medicine
  • Residencies: Medicine - Columbia Presbyterian Medical Center
  • Fellowships: Oncology/Hematology - Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College
  • Board Certifications: Medical Oncology

See My Colleagues


Visit PubMed for a full listing of Michael J. Morris’ journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.


Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.

Learn more Arrow rightAn icon showing an arrow pointing to the right.